Inherited aortopathy, which is characterized by aortic dilation or aortic aneurysms/dissection, may be syndromic, as occurs in Marfan syndrome (MFS)[@b1], Loeys-Dietz syndrome (LDS)[@b2], Ehlers-Danlos syndrome, vascular type (vEDS)[@b3], and Shprintzen-Goldberg syndrome (SGS)[@b4], or non-syndromic, in which abnormalities are restricted to the aorta[@b5]. Although these diseases have their own unique characteristics, they also share some clinical manifestations, which makes the precise diagnosis and treatment strategy difficult. Previous studies demonstrated that the mortality after the rupture of thoracic aortic aneurysms (TAA) was as high as 97%, with a median survival time of 3 days[@b6], and the acute aortic dissection patients had a higher re-intervention rate, even if they survived the initial surgery[@b7]. Hence, early diagnosis is important because it provides valuable time for prophylactic measures to be taken. Genetic testing can help to detect the pathogenic genes/mutations involved in the disease and confirm the diagnosis before the full development of symptom, thereby reduce the rate of cardiovascular events.

Several causative genes for syndromic aortopathy have been identified, including *FBN1* for Marfan syndrome[@b8], *TGFBR1/2, SMAD3, TGFB2* for Loeys-Dietz syndrome[@b9][@b10][@b11], *COL3A1* for Ehlers-Danlos syndrome, vascular type[@b12], and *SLC2A10* for arterial tortuosity syndrome[@b13]. Additionally, an increasing number of genes have been implicated in the pathogenesis of thoracic aortic aneurysms, including *MYH11, ACTA2, NOTCH1, MYLK, PRKG1,* and *SKI*[@b14].

The clinical utility of genetic testing for heritable aortopathy is now well established[@b15][@b16], and several commercial panel tests containing different numbers of genes are available. However, due to the lack of a database for Chinese population, it is challenging to determine the pathogenicity of genetic variants for Chinese patients. To identify genetic mutations and make a precise diagnosis and to establish an aortopathy genetic database for Chinese population, we recruited 248 probands with aortic disease or Marfan syndrome in Fuwai hospital and performed gene panel testing involving 15 genes related to inherited aortopathy. Herein, we report the molecular findings from the 248 patients, which, at present, is the largest group of aortic disease patients ever reported in China. Further, we optimized the analysis pipeline by adding quality control steps and lowering the false positive rate.

Results
=======

Aortopathy panel performance
----------------------------

Sequencing of the 15 aortopathy genes ([Table 1](#t1){ref-type="table"}) in the 248 samples yielded a mean depth of \~350X and coverage of 98.7% ([Supp. Figure S1](#S1){ref-type="supplementary-material"}). Exons in *FBN1* with low (\<20X) or no coverage were subject to Sanger sequencing to obtain 100% coverage. In addition, potential pathogenic mutations and rare variant of unknown significance (VUS) were confirmed using Sanger sequencing.

Automated and optimal analysis pipeline
---------------------------------------

Initially, we used Ion Torrent Suite and Ion Reporter, which were provided by Life Tech, to accomplish the alignment, variant calling and annotation processes. Based on our growing data and experience, we developed an automated and optimal analysis plugin named iAorta, which allowed us to automatically pick up suspected pathogenic mutations or VUS from polymorphism or false-positive variants, add quality control steps to assess the sequencing quality and indicate possible false-negative variants, and remove frequent false-positive mutations based on our 248 samples. Compared with Ion Torrent Suite, the analysis strategy of iAorta was to relax the filter conditions to avoid false negative variants. Subsequently, according to the accumulated data, false positive variants were removed.

After re-analyzing the sequencing data from our 248 samples by iAorta, we obtained a false-negative list ([Supp. Table S1](#S1){ref-type="supplementary-material"}). We also generated a false-positive list after validation by Sanger sequencing. Most of the false-positive mutation were scattered over the end of amplicon and were likely introduced by degenerate primers and mapping error. For frameshift/non-frameshift indels, we evaluated the confidence based on the coverage depth (\>20x), allele frequency (\>10%), and strand bias (both forward and reverse allele reads \>3, both forward/reverse and reverse/forward \>0.7). If any of the three conditions was not satisfied, the sample was classified as a possible false-positive mutation and marked as "DropIndel". After we removed some frequent false-positive mutations ([Supp. Table S2](#S1){ref-type="supplementary-material"}) and modified our analysis pipeline, the false-positive rate decreased from 25.4% to 15.4%.

In addition, all of the bases coding cysteine in *FBN1* were assigned as a "hotspot". When there was a "NoCall" in the position, an alert for a possible false negative region was generated, and the exon was then Sanger sequenced.

Molecular findings of the aortopathy cohort
-------------------------------------------

A total of 248 patients (162 males and 86 females) with Marfan syndrome and its related aortic diseases, were enrolled in our cohort, with a mean age of 46 years (5--60 years). The primary clinical diagnoses of these probands submitted for aortopathy panel testing were summarized in [Table 2](#t2){ref-type="table"}. Among the 248 individuals, 92 (37.1%) were tested positive for a (likely) pathogenic mutation, 70 (28.2%) had a VUS, and 86 (34.7%) were tested negative using the 15-gene aortopathy panel. Most of the (likely) pathogenic mutations were located in the *FBN1* gene, because the cysteine residues in this gene were evolutionarily conserved and had essential functions[@b17]. Accordingly, the destruction or generation of a cysteine residue suggested that the mutation was probably pathogenic[@b18]. The pathogenicity of missense mutations in other genes was difficult to define due to the lack of functional studies or strong family segregation evidence. (Likely) pathogenic mutations were identified in *FBN1*, *TGFBR1/2, ACTA2, MYH11, COL3A1* and *SLC2A10* ([Table 3](#t3){ref-type="table"}), and VUS were identified in all 15 genes in the panel.

A genotype-phenotype correlation between *FBN1* mutation type and aortic events was also investigated. Of all the 248 probands, 82 were tested positive for a (likely) pathogenic *FBN1* mutation. Among them, 28 had undergone surgery due to a life-threatening aortic dissection, 21 had undergone prophylactic surgery due to aortic aneurysm, 6 had a valve replacement due to severe valvular disease, 4 had mild aortic dilation and came for genetic testing because of other system manifestations in Marfan syndrome, and the remaining 24 patients had no complete clinical information. We attempted to study the correlation between *FBN1* mutation type and severity of aortic events, and the results were listed in [Table 4](#t4){ref-type="table"}. Among patients with a *FBN1* truncating or splicing mutation, 15 suffered from life-threatening aortic dissection, 5 had severe valvular disease, while 9 had aortic aneurysm and therefore underwent prophylactic surgery. Besides, 3 patients with one *FBN1* truncating or splicing mutation only showed mild aortic dilation probably due to a young age, therefore they were not excluded to have aortic disease progression in the future. Additionally, in the aneurysm group, patients with a *FBN1* truncating or splicing mutation took a prophylactic surgery at a younger age (25.6y vs. 33.4y) than those with a missense mutation. These results suggested that patients with *FBN1* truncating or splicing mutation were more prone to developing severe aortic disease or valvular disease.

Variant reclassification
------------------------

When available, family segregation studies were performed to assist in the variant classification. In this study, 18 variants were reclassified through the family segregation study in our patient cohort ([Table 5](#t5){ref-type="table"}).

The *FBN1*, c.1427G\>A (p.Cys476Tyr) variant in case AD246, which presented a classic MFS phenotype and a positive family history, was originally classified as likely pathogenic. However, it was downgraded to VUS after familial targeted sequencing revealed that the variant was not present in his affected sibling. Thus, whole exome sequencing (WES) was performed in the proband and his two affected sisters to find other potential pathogenic mutations. Another interesting case was as reported in our previously published paper[@b19]. The variant *TGFBR2*, c.1142G\>C (p.Arg381Pro) was detected in a 5 year-old boy, who had a distinctive LDS phenotype of descending pseudoaneurysm, artery tortuosity, bifid uvula, hypertelorism. However, the mutation was also carried by his healthy father, which made its pathogenicity doubtful, although it was once reported as pathogenic in a LDS patient[@b20]. Further functional study was necessary to confirm its pathogenicity.

Discussion
==========

Genetic testing is important for the early and accurate diagnosis of diseases. Although patients with Marfan syndrome and its related diseases are all characterized with aortopathy, they may differ in their progress of aortic aneurysm/dissection. It was previously reported that LDS patients had more aggressive arterial disease and rupture, with a median survival time of only 26 years[@b2], compared with 48 years for patients with vEDS[@b3] and 70 years for those with MFS[@b21]. However, with early diagnosis and proper management, LDS was particularly amendable to treatment. The incidence of fatal intraoperative or postoperative complications with vascular surgery was only 1.7% in LDS[@b2] compared with approximately 45% in vEDS[@b3].

The NGS (next generation sequencing)-based assays for screening inherited aortopathy genes have been well established and utilized in some laboratories[@b15][@b16]. Sequencing data processing and analysis is the key point, and validating the candidate causal variants via Sanger sequencing is the most time-consuming step. Therefore, how to optimize the algorithms to lower the false-positive rate without raising the false-negative rate is extremely important. In our study, we developed an automated and optimized pipeline named iAorta that automatically accomplished read mapping, recalibration, quality control, alignment, variant calling, annotation and variant filtering. Compared to the Ion Torrent Suite and Ion Reporter software, which were provided by Life Tech, iAorta was used more flexibly, which allowed us to automatically pick up suspected pathogenic mutations and VUS from polymorphism or false-positive variants, add quality control steps to assess the sequencing quality and to indicate possible false-negative variants, remove frequent false-positive mutations based our existing data and drop the low confidence indel variants to reduce the false-positive rate.

In addition to data processing and analysis, the classification of variant pathogenicity is challenging. Novel variants should be subjected to functional studies, but these are costly, time consuming, and often impractical in the clinical setting. Therefore, classification is largely dependent on database knowledge, which is extremely deficient in Chinese populations. The aim of our study was to build the largest shared database for Chinese aortopathy patients. In our cohort, 92 patients (37.1%) tested positive for a (likely) pathogenic mutation, including 84 Marfan patients, as well as 3 LDS, 3 TAAD (thoracic aortic aneurysms and aortic dissection), 1 vEDS and 1 arterial tortuosity syndrome case. Additionally, the results of the patients' family members were helpful for pathogenicity classification. Specifically, in our study, 18 variants were reclassified based on family segregation studies. After screening by the current gene panel testing, some cases remained negative, although they presented classical clinical phenotypes or family histories. As a follow-up, we intend to perform MLPA (Multiplex Ligation-dependent Probe Amplification) or WES on these samples to find large deletion/duplication or new potential causative genes. Besides, in more than one third of the patients, no suspected mutation was identified, which suggested that additional aortopathy genes might exist. We anticipate that clinical sensitivity will rise as additional genes are identified and included in the panel and that VUS can be reclassified with increasing numbers of samples and family segregation studies. Several recently identified TAA genes, such as *TGFB3*[@b22], *MFAP5*[@b23], *MAT2A*[@b24] and *LOX*[@b25], can be added to the gene list.

A genotype-phenotype correlation between *FBN1* mutation type and aortic events was investigated. Interestingly, we found that patients with a *FBN1* truncating or splicing mutation were more prone to developing severe aortic disease or valvular disease than the patients with a *FBN1* missense mutation. Similarly, Baudhuin *et al*. once reported that a higher frequency of truncating or splicing *FBN1* variants was observed in MFS patients with an aortic event than in those without a reported aortic event[@b26]. However, the mechanism whereby *FBN1* truncating or splicing mutations exert their effect on aneurysm progression and severity is not clear, which deserves our further investigation.

In summary, our data further expands the *FBN1* mutation spectrum and offer evidence for the genotype-phenotype correlation given that Marfan patients with a *FBN1* truncating or splicing mutation are more prone to developing severe aortic disease or valvular disease. The aortopathy panel assay undoubtedly presents a highly valuable clinical tool and lays the foundation for further study. We are dedicated to constructing the largest Chinese aortopathy genetic database and continually improving our testing quality.

Materials and Methods
=====================

Patients and consent
--------------------

The study was approved by the ethics committee of Fuwai hospital and adhered to the Declaration of Helsinki. All experimental protocols were approved by the ethics committee of Fuwai hospital, and were carried out in accordance with the approved guidelines. All of the patients enrolled in this study were referred by the center of vascular surgery in Fuwai hospital. Each individual accepting the genetic test was adequately informed regarding the benefits and risks of the test and signed the consent form.

Between Feb 2014 and Apr 2016, we tested a total of 248 patients with various aortic phenotypes, such as early onset aortopathy patients with no apparent secondary causes and (suspected) Marfan patients. The follow-up study was carried out in subsequent clinic visits to the outpatient department and by telephone interviews.

Gene panel testing
------------------

A custom-designed gene panel containing 15 genes known to be associated with Marfan syndrome and its related aortic diseases was ordered from Life Tech, USA. The size of the panel was 168.67 kb, with coverage of 99.39% of the target regions.

Genomic DNA (deoxyribonucleic acid) was extracted from EDTA (eathylene diamine tetraacetic acid)--anticoagulated whole blood, and checked to assure the quality and quantity before processing. Library preparation was performed according to the manufacturer's instructions (Ion AmpliSeq^TM^ library kit 2.0, Life Technologies, Inc.). Pooled libraries (up to 12--15 samples per chip) were sequenced on the Ion 318^TM^ Chip on Life PGM^TM^ instrument.

Suspected pathogenic variants and VUS were confirmed using Sanger sequencing. Exons in *FBN1* with low (\<20X) or no coverage were also subjected to Sanger sequencing to obtain 100% coverage.

Bioinformatics analysis
-----------------------

To perform the analysis automatically, the iAorta plugin was developed based on the sequencing platform for ion torrent PGM™. The pipeline consisted of read mapping, recalibration, quality control, variant calling, annotation and variant filtering. The annotation included genetic reference sequences, genomic and cDNA positions, amino acid changes, and related information available from public databases, such as 1000 Genomes, dbSNP142 (National Center for Biotechnology Information, <http://www.ncbi.nlm.nih.gov/SNP/>), NHLBI Grand Opportunity Exome Sequencing Project (ESP6500) (<https://esp.gs.washington.edu/drupal/>), ExAC03 (<http://exac.broadinstitute.org>), ClinVar, DrugBank, Online Mendelian Inheritance in Man (OMIM), Uniprot (<http://www.uniprot.org>), and the Human Gene Mutation Database (HGMD), Pfam (<http://pfam.xfam.org>). The *in-silico* based computation analysis was carried out using a suite of bioinformatics tools, including SIFT, Polyphen2, MutationTaster, Grantham, and PolyP.

Because most of the heritable aortopathies were autosomal-inherited rare Mendelian disease, the variants with a minor allele frequency (MAF) \> 1% in the following databases were filtered out: the 1000 Genomes, ESP6500, ExAC03.

Variant classification
----------------------

Variants were analyzed for pathogenicity according to the recommendations from the American College of Medical Genetics (ACMG). Specifically, the analysis was based on the following criteria: (i) whether they were previously reported by functional study or family segregation study; (ii) the nature of the variant (e.g., nonsense, frameshift indel, or splicing mutations (intron ±1 or ±2)); (iii) variant frequency in the 1000 Genomes, Exome Sequencing Project (ESP6500) and ExAC03; (iv) conservation of the altered residue; (v) in-silico based computational prediction (SIFT, PholyPhen2, or MutationTaster); (vi) de novo mutation; and (vii) family segregation studies. Based on this information, a variant was classified into one of the 5 following categories: benign, likely benign, unknown significance, likely pathogenic or pathogenic[@b27].
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###### Aortopathy panel genes.

  Gene              Locus                                      Protein                                                                  Disease                                     Exons   Amplicons   Coverage
  ----------- ------------------ -------------------------------------------------------------------- ---------------------------------------------------------------------------- ------- ----------- ----------
  *ACTA2*         10q22--q24                     actin, alpha 2, smooth muscle, aorta                                                     TAAD                                       10        15          1
  *COL3A1*           2q31                            collagen, type III, alpha 1                                                          vEDS                                       51        66        0.998
  *FBN1*           15q21.1                                   fibrillin 1                               Marfan, MASS, Mitral valve prolapse syndrome, Ectopia lentis syndrome, SGS    66        106         1
  *FBN2*          5q23--q31                                  fibrillin-2                                                                  CCA                                        65        99          1
  *MYH11*      16p13.13--p13.12                               myosin-11                                                                   TAAD                                       43        61        0.971
  *MYLK*             3q21                      myosin light chain kinase, smooth muscle                                                   TAAD                                       34        66        0.983
  *NOTCH1*          9q34.3                     neurogenic locus notch homolog protein 1                                                   TAAD                                       34        78        0.892
  *PRKG1*          10q11.2                         cGMP-dependent protein kinase 1                                                        TAAD                                       21        23        0.934
  *SKI*            1p36.33                                   ski oncogene                                                                 SGS                                         8        19        0.971
  *SLC2A10*        20q13.1        solute carrier family 2, facilitated glucose transporter member 10                          Arterial tortuosity syndrome                            8        26        0.977
  *SMAD3*          15q22.33                   mothers against decapentaplegic homolog 3                                                LDS, TAAD                                     13        46        0.922
  *SMAD4*          18q21.1                    mothers against decapentaplegic homolog 4                                                   TAAD                                       12        54          1
  *TGFB2*            1q41                         transforming growth factor beta-2                                                       LDS                                         8        36        0.922
  *TGFBR1*        9q33--q34                            TGF-beta receptor type-1                                                         LDS,TAAD                                     11        39          1
  *TGFBR2*           3p22                              TGF-beta receptor type-2                                                        LDS, TAAD                                      9        29          1

LDS, Loeys-Dietz syndrome; SGS, Shprintzen-Goldberg syndrome; TAAD, Thoracic aortic aneurysms and aortic dissection; MASS, The acronym MASS stands for mitral valve prolapse, myopia, borderline and non-progressive aortic enlargement, and nonspecific skin and skeletal findings that overlap with those seen in Marfan syndrome; vEDS, Ehlers-Danlos syndrome, vascular type; CCA, Congenital contractural arachnodactyly.

###### Summary of primary diagnosis and genetic results of 248 probands in our cohort.

  Primary Diagnosis                 Cases   Genetic Results       
  -------------------------------- ------- ----------------- ---- ----
  Marfan syndrome                    65           55          5    5
  Suspected Marfan syndrome          52           29          7    16
  Suspected Loeys-Dietz syndrome     10            3          7    0
  Non-syndromic aortic events        121           5          51   65
  Total                              248          92          70   86

###### (Likely) Pathogenic mutations and VUS detected in our cohort.

  Gene          Transcript    Exon/Intron      Nucleotide change       Protein change          De novo            Pathogenicity     Report Ref (PMID)
  ----------- -------------- ------------- -------------------------- ---------------- ----------------------- ------------------- -------------------
  *ACTA2*       NM_001613        exon7             c.773G\>A            p.Arg258His              NA             Likely Pathogenic       19409525
  *ACTA2*       NM_001613        exon2             c.116G\>A             p.Arg39His              NA             Likely Pathogenic       19409525
  *COL3A1*      NM_000090       exon41             c.2932G\>C           p.Gly978Arg              NA             Likely Pathogenic            
  *FBN1*        NM_000138       exon33             c.4022A\>G           p.Asn1341Ser             NA             Likely Pathogenic       10464652
  *FBN1*        NM_000138       exon17             c.2055C\>G           p.Cys685Trp              NA             Likely Pathogenic       12203987
  *FBN1*        NM_000138      intron55           c.6740-1G\>A                                 De novo             Pathogenic                
  *FBN1*        NM_000138       exon47             c.5788G\>C           p.Asp1930His             NA             Likely Pathogenic       17657824
  *FBN1*        NM_000138       exon29             c.3496T\>C           p.Cys1166Arg             NA             Likely Pathogenic            
  *FBN1*        NM_000138       exon28      c.3440_3441insTTCAGCTGTC    p.Ser1147fs              NA                Pathogenic                
  *FBN1*        NM_000138       exon40         c.4897_4898insCGCT       p.Cys1633fs              NA                Pathogenic                
  *FBN1*        NM_000138      intron55           c.6739+1G\>T                                   NA                Pathogenic                
  *FBN1*        NM_000138       exon33             c.3995delA           p.Asn1332fs     Inherited from mother      Pathogenic                
  *FBN1*        NM_000138       exon64             c.7871A\>C           p.Asn2624Thr             NA             Likely Pathogenic       19293843
  *FBN1*        NM_000138      intron13           c.1589-1G\>A                                   NA                Pathogenic                
  *FBN1*        NM_000138       exon54             c.6569G\>A           p.Cys2190Tyr             NA             Likely Pathogenic            
  *FBN1*        NM_000138       exon61             c.7477C\>T           p.Gln2493Ter             NA                Pathogenic                
  *FBN1*        NM_000138        exon7             c.643C\>T            p.Arg215Ter              NA                Pathogenic           11139245
  *FBN1*        NM_000138       exon58           c.7039_7040del         p.Met2347fs              NA                Pathogenic                
  *FBN1*        NM_000138       exon37             c.4527dupT           p.Ile1510fs              NA                Pathogenic                
  *FBN1*        NM_000138       exon13             c.1481G\>A           p.Cys494Tyr              NA             Likely Pathogenic       24501682
  *FBN1*        NM_000138       exon66           c.8525_8529del         p.Leu2842fs     Inherited from mother      Pathogenic                
  *FBN1*        NM_000138       exon28             c.3352C\>T           p.Gln1118Ter           De novo             Pathogenic                
  *FBN1*        NM_000138       exon42             c.5162G\>A           p.Cys1721Tyr             NA             Likely Pathogenic        9399842
  *FBN1*        NM_000138       exon37             c.4532G\>T           p.Cys1511Phe           De novo          Likely Pathogenic            
  *FBN1*        NM_000138       exon40             c.4831delC           p.Gln1611fs              NA                Pathogenic                
  *FBN1*        NM_000138       exon62             c.7606G\>A           p.Gly2536Arg             NA             Likely Pathogenic       11524736
  *FBN1*        NM_000138       exon44             c.5372G\>A           p.Cys1791Tyr             NA             Likely Pathogenic       11700157
  *FBN1*        NM_000138       exon63             c.7754T\>C           p.Ile2585Thr             NA             Likely Pathogenic       10464652
  *FBN1*        NM_000138       exon64             c.7955G\>A           p.Cys2652Tyr             NA             Likely Pathogenic       17627385
  *FBN1*        NM_000138       exon13             c.1585C\>T           p.Arg529Ter              NA                Pathogenic           17663468
  *FBN1*        NM_000138       exon31             c.3778G\>T           p.Glu1260Ter             NA                Pathogenic           10464652
  *FBN1*        NM_000138       exon58        c.7010_7011delinsCAC      p.Gly2337fs              NA                Pathogenic                
  *FBN1*        NM_000138       exon50             c.6071G\>A           p.Cys2024Tyr             NA             Likely Pathogenic            
  *FBN1*        NM_000138       exon33        c.4081_4082delinsAA       p.Cys1361Asn             NA             Likely Pathogenic            
  *FBN1*        NM_000138       exon49             c.6000C\>A           p.Cys2000Ter             NA                Pathogenic                
  *FBN1*        NM_000138       exon49       c.4544_4546delinsAGAT      p.Pro1515fs              NA                Pathogenic                
  *FBN1*        NM_000138      intron21           c.2540-2A\>G                                   NA                Pathogenic                
  *FBN1*        NM_000138      intron49           c.6037+2T\>C                                   NA                Pathogenic                
  *FBN1*        NM_000138       exon24             c.2740T\>C           p.Cys914Arg              NA             Likely Pathogenic            
  *FBN1*        NM_000138       exon16             c.1884C\>A           p.Cys628Ter              NA                Pathogenic           12068374
  *FBN1*        NM_000138       exon15             c.1794C\>A           p.Cys598Ter              NA                Pathogenic                
  *FBN1*        NM_000138       exon53             c.6446A\>G           p.Tyr2149Cys             NA             Likely Pathogenic       24793577
  *FBN1*        NM_000138      intron27           c.3337+1G\>A                                 De novo             Pathogenic                
  *FBN1*        NM_000138       exon45             c.5434T\>C           p.Cys1812Arg           De novo          Likely Pathogenic       19533785
  *FBN1*        NM_000138      intron16           c.1960+1delG                                 De novo             Pathogenic                
  *FBN1*        NM_000138       exon45             c.5455C\>T           p.Gln1819Ter             NA                Pathogenic                
  *FBN1*        NM_000138       exon35             c.4331G\>A           p.Cys1444Tyr             NA             Likely Pathogenic            
  *FBN1*        NM_000138       exon21             c.2433C\>G           p.Cys811Trp              NA             Likely Pathogenic       15241795
  *FBN1*        NM_000138       exon64             c.7868dupA           p.His2623fs     Inherited from mother      Pathogenic                
  *FBN1*        NM_000138       exon48             c.5873G\>A           p.Cys1958Tyr             NA             Likely Pathogenic       21907952
  *FBN1*        NM_000138       exon63             c.7711T\>C           p.Cys2571Arg             NA             Likely Pathogenic       16222657
  *FBN1*        NM_000138       exon56             c.6867T\>A           p.Cys2289Ter             NA                Pathogenic                
  *FBN1*        NM_000138      intron28           c.3464-2A\>G                                   NA                Pathogenic                
  *FBN1*        NM_000138       exon12             c.1374T\>A           p.Tyr458Ter            De novo             Pathogenic                
  *FBN1*        NM_000138       exon40             c.4897T\>C           p.Cys1633Arg             NA             Likely Pathogenic            
  *FBN1*        NM_000138       exon11             c.1285C\>T           p.Arg429Ter              NA                Pathogenic           11933199
  *FBN1*        NM_000138       exon17          c.1968_1969dupCA       p.HisiSer656fs            NA                Pathogenic                
  *FBN1*        NM_000138       exon13         c.1561_1562insCAGA        p.Ser521fs              NA                Pathogenic                
  *FBN1*        NM_000138       exon35             c.4292G\>A           p.Cys1431Tyr             NA             Likely Pathogenic       21542060
  *FBN1*        NM_000138      intron48           c.5918-1G\>A                                 De novo             Pathogenic                
  *FBN1*        NM_000138      intron48           c.5917+2T\>C                                   NA                Pathogenic                
  *FBN1*        NM_000138       exon14             c.1633C\>T           p.Arg545Cys              NA             Likely Pathogenic        9338581
  *FBN1*        NM_000138        exon9             c.897T\>G            p.Cys299Trp              NA             Likely Pathogenic            
  *FBN1*        NM_000138        exon7             c.640G\>A            p.Gly214Ser              NA             Likely Pathogenic       15733436
  *FBN1*        NM_000138       exon45             c.5540G\>T           p.Cys1847Phe    Inherited from father   Likely Pathogenic            
  *FBN1*        NM_000138       exon64             c.7921C\>T           p.Gln2641Ter             NA                Pathogenic                
  *FBN1*        NM_000138      intron28           c.3463+1G\>T                                   NA                Pathogenic                
  *FBN1*        NM_000138       exon27             c.3217delG           p.Glu1073fs              NA                Pathogenic                
  *FBN1*        NM_000138       exon25             c.2987G\>A           p.Cys996Tyr              NA             Likely Pathogenic            
  *FBN1*        NM_000138       exon56             c.6806T\>C           p.Ile2269Thr             NA             Likely Pathogenic       10464652
  *FBN1*        NM_000138       exon66             c.8547T\>G           p.Tyr2849Ter             NA                Pathogenic           21034599
  *FBN1*        NM_000138       exon66             c.6296G\>A           p.Cys2099Tyr             NA             Likely Pathogenic            
  *FBN1*        NM_000138        exon2              c.3G\>A              p.Met1Ile               NA                Pathogenic                
  *FBN1*        NM_000138       exon66             c.1098G\>C           p.Trp366Cys              NA             Likely Pathogenic            
  *FBN1*        NM_000138       exon66             c.5841C\>A           p.Cys1947Ter             NA                Pathogenic                
  *FBN1*        NM_000138        exon6             c.529T\>C            p.Cys177Arg            De novo          Likely Pathogenic       16222657
  *FBN1*        NM_000138       exon42            c.5065+1G\>A                                   NA                Pathogenic           17627385
  *FBN1*        NM_000138       exon62           c.7636_7642del         p.Gly2546fs              NA                Pathogenic                
  *FBN1*        NM_000138        exon3             c.184C\>T             p.Arg62Cys              NA             Likely Pathogenic       11826022
  *FBN1*        NM_000138       exon34             c.4096G\>A           p.Glu1366Lys             NA             Likely Pathogenic       14695540
  *FBN1*        NM_000138       exon48            c.5788+1G\>A                                   NA                Pathogenic           11702223
  *FBN1*        NM_000138       exon53             c.6431A\>G           p.Asn2144Ser             NA             Likely Pathogenic        8504310
  *MYH11*      NM_001040114    intron33           c.4599+1G\>A                                   NA                Pathogenic           21937134
  *SLC2A10*     NM_030777        exon2           c.1053_1054del          p.Ser351fs              NA                Pathogenic                
  *TGFBR1*      NM_004612        exon9             c.1459C\>T           p.Arg487Trp              NA             Likely Pathogenic       16928994
  *TGFBR1*      NM_004612        exon4            c.678_680del          p.226_227del           De novo          Likely Pathogenic            
  *TGFBR2*     NM_001024847      exon7             c.1524dupT            p.Cys508fs              NA                Pathogenic                

NA, not available.

###### *FBN1* mutation type and mean average age in patients with various aortic events.

                        Aortic dissection       Aortic aneurysm   Valvular disease   Marfan with mild aortic dilation  
  --------------------- ---------------------- ----------------- ------------------ ---------------------------------- -----------
  Truncating            Frameshift insertion       3 (30.0y)         1 (18.0y)                  1 (33.0y)               1 (27.0y)
  Frameshift deletion   1 (24.0y)                  2 (18.5y)         1 (14.0y)                  1 (16.0y)              
  Stopgain              6 (33.2y)                  3 (24.7y)         2 (31.5y)                  1 (17.0y)              
  Splicing              5 (33.6y)                  3 (38.0y)         1 (16.0y)                      0                  
  Truncating+Splicing   15 (32.1y)                 9 (25.6y)         5 (25.2y)                  3 (20.0y)              
  Missense              13 (36.5y)                12 (33.4y)         1 (17.0y)                  1 (39.0y)              

y, years old.

###### Reclassified variants.

  Gene         Transcript    Exon/Intron   Nucleotide change   Protein change    Variant called     Variant reclassification   Reclassification based on   PopFreqMax   Report Ref (PMID)
  ---------- -------------- ------------- ------------------- ---------------- ------------------- -------------------------- --------------------------- ------------ -------------------
  *COL3A1*     NM_000090       exon48         c.3776C\>T        p.Ala1259Val           VUS                   Benign               Family segregation         0.0017         22001912
  *FBN1*       NM_000138       exon25         c.2953G\>A        p.Gly985Arg     Likely Pathogenic            Benign               Family segregation           .            11700157
  *FBN1*       NM_000138       exon66         c.8308C\>T        p.His2770Tyr           VUS                   Benign               Family segregation         0.0001             .
  *FBN1*       NM_000138       exon12         c.1427G\>A        p.Cys476Tyr     Likely Pathogenic             VUS                 Family segregation           .                .
  *FBN1*       NM_000138       exon53         c.6380A\>G        p.Asp2127Gly           VUS                   Benign               Family segregation           .                .
  *FBN1*       NM_000138       exon62         c.7627A\>C        p.Asn2543His           VUS                   Benign               Family segregation           .                .
  *FBN1*       NM_000138       exon50         c.6050G\>A        p.Cys2017Tyr    Likely Pathogenic            Benign               Family segregation           .                .
  *FBN1*       NM_000138       exon59         c.7231G\>A        p.Asp2411Asn           VUS                   Benign               Family segregation           .                .
  *MYH11*     NM_001040114     exon20         c.2293C\>A        p.Pro765Thr            VUS                   Benign               Family segregation         0.002              .
  *MYH11*     NM_001040114     exon31         c.4090G\>A        p.Glu1364Lys           VUS                   Benign               Family segregation         0.0001             .
  *MYLK*       NM_053025       exon10          c.998C\>T        p.Pro333Leu            VUS                   Benign               Family segregation           .                .
  *NOTCH1*     NM_017617       exon34         c.6351C\>A        p.Asn2117Lys           VUS                   Benign               Family segregation         0.0004             .
  *NOTCH1*     NM_017617       exon21         c.3401A\>G        p.Gln1134Arg           VUS                   Benign               Family segregation           .                .
  *NOTCH1*     NM_017617       exon21         c.3402G\>C        p.Gln1134His           VUS                   Benign               Family segregation           .                .
  *SMAD3*      NM_005902        exon1           c.5C\>T          p.Ser2Leu             VUS                   Benign               Family segregation           .                .
  *SMAD3*      NM_005902        exon1        c.147_155del        p.49_51del            VUS               Likely Benign            Family segregation           .                .
  *SMAD4*      NM_005359        exon6          c.700A\>C        p.Ser234Arg            VUS                   Benign               Family segregation        0.00011             .
  *TGFBR2*    NM_001024847      exon5         c.1142G\>C        p.Arg381Pro     Likely Pathogenic             VUS                 Family segregation           .            16283890

VUS, variant of unknown significance.

[^1]: These authors contributed equally to this work.
